



## MEDICAL TIPS

### ROVASTAT TABLETS

Issue V, No. 17, 2022

#### **Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials**

*Joseph P et al. Cardiovasc Res 2022; 118(3): 897-903*

- A meta-analysis was conducted to examine the association of rosuvastatin with the risk of venous thromboembolism (VTE).
- Data from two randomized controlled trials in 30,507 participants over 3.62 years, in individuals with no prior history of vascular disease but at intermediate CV risk were analysed.
- Associations between rosuvastatin and VTE was examined based on risk factors such as age, sex, obesity, smoking, lipid levels, BP ,CRP levels and history of cancer.
- Among the VTE events, rosuvastatin was associated with a large proportional reduction in the risk of VTE.

**Rosuvastatin was associated with a 47% proportional reduction in the risk of VTE, and its effect were consistent both in the presence or absence of VTE-related clinical risk factors.**

